Correction to: Association of bowel radiation dose-volume with skeletal muscle loss during pelvic intensity-modulated radiotherapy in cervical cancer

Jie Lee^{1,2} · Jhen-Bin Lin³ · Meng-Hao Wu¹ · Chih-Long Chang^{2,4} · Ya-Ting Jan⁵ · Fang-Ju Sun⁶ · Yu-Jen Chen¹

Published online: 25 November 2021

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to: Supportive Care in Cancer (2021) 29:5497–5505
<https://doi.org/10.1007/s00520-021-06131-x>

The correct Table 4 should be the below:

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00520-021-06131-x>.

✉ Jie Lee
sinus.5706@mmh.org.tw

¹ Department of Radiation Oncology, MacKay Memorial Hospital, 92, Section 2, Chung Shan North Road, Taipei 10449, Taiwan

² Department of Medicine, MacKay Medical College, New Taipei City, Taiwan

³ Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan

⁴ Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan

⁵ Department of Radiology, MacKay Memorial Hospital, Taipei, Taiwan

⁶ Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan

Table 4 Cox proportional hazards model for overall survival

Variable	Univariable		Multivariable	
	Hazard ratio (95% CI)	<i>p</i> -value	Hazard ratio (95% CI)	<i>p</i> -value
Age				
< 70 years	Reference		Reference	
≥ 70 years	1.63 (0.96–2.76)	0.07	1.23 (0.68–2.25)	0.50
ECOG performance status				
0	Reference		-	-
1	1.21 (0.52–2.83)	0.66	-	-
FIGO stage				
IB-II	Reference		Reference	
III-IVA	1.80 (1.04–3.10)	0.04	1.97 (1.09–3.57)	0.03
PLNs involvement				
Negative	Reference		-	-
Positive	1.21 (0.72–2.05)	0.47	-	-
Pathology				
Squamous cell carcinoma	Reference		Reference	
Adenocarcinoma	3.19 (1.71–5.94)	< 0.001	2.16 (1.03–4.50)	0.04
SCC-Ag level, continuous	1.00 (0.99–1.01)	0.50	-	-
NLR				
≤ 3	Reference		Reference	
> 3	2.42 (1.42–4.13)	0.001	2.45 (1.32–4.54)	0.005
Pre-treatment SMI	0.97 (0.933–1.003)	0.08	0.99 (0.95–1.04)	0.70
SMI change				
SMI maintain	Reference		Reference	
SMI loss (≥ -10.0%)	8.02 (4.70–13.69)	< 0.001	5.73 (2.90–11.34)	< 0.001
Pre-treatment SMD	1.008 (0.98–1.04)	0.60	-	-
SMD change				
SMD maintain	Reference		Reference	
SMD loss (≥ -10.0%)	3.66 (2.17–6.15)	< 0.001	1.83 (0.94–3.56)	0.08
Pre-treatment TATI	0.994 (0.988–1.001)	0.07	0.998 (0.989–1.006)	0.58
TATI change				
TATI maintain	Reference		Reference	
TATI loss (≥ -10.0%)	1.99 (1.18–3.37)	0.01	1.20 (0.64–2.22)	0.57

Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; NLR, neutrophil-lymphocyte ratio; PLN, pelvic lymph node; SCC-Ag, squamous cell carcinoma antigen; SMD, skeletal muscle density; SMI, skeletal muscle index; TATI, total adipose tissue index